Loading...

OCUL OCULAR THERAPEUTIX INC US FDA Inspections 8-K Filing

CLR

CL

OCULAR THERAPEUTIX INC

(OCUL)

2024 8-K

Clinical Trial Update

Financial Results Announced

Management Change

Clinical Trial Update

FDA Application Update

Financial Results Released

Stock Offering Details

Clinical Trial Updates

Financial Statements

Equity Offerings

Financial Results

Financial Results

CEO Compensation Update

Financial Results

Stock Incentive Plan

Management Appointment

Financial Results Announcement

Annual Meeting Approval

Reduction in Force

Financial Results Announcement

Appointment of Pravin U. Du...

Management Agreement Modifi...

Financial Results Announcement

Private Placement and Manag...

FDA Agreement Modification ...

Public Offering

Financial Results Announcement

Presentation at EURETINA In...

Clinical Trial Initiation

Financial Results Announcement

Annual Meeting Approval

Clinical Trial Results

Financial Results Announcement

Amendment to Credit Agreement

Financial Results Announcement

Earnings Update

External Links:

Ocular Therapeutix, Inc. announced that the FDA has agreed to a Special Protocol Assessment (SPA) Agreement Modification for their Phase 3 clinical trial evaluating AXPAXLI for the treatment of wet age-related macular degeneration (wet AMD).

AI Assistant

OCULAR THERAPEUTIX INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.